Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Assets (2016 - 2026)

Corvus Pharmaceuticals' Other Non-Current Assets history spans 11 years, with the latest figure at $1.7 million for Q1 2026.

  • Quarterly Other Non-Current Assets rose 173.45% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2026, up 173.45% year-over-year, with the annual reading at $855000.0 for FY2025, 35.28% up from the prior year.
  • Other Non-Current Assets came in at $1.7 million for Q1 2026, up from $855000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.7 million in Q1 2026 to a low of $89000.0 in Q3 2023.
  • The 5-year median for Other Non-Current Assets is $236000.0 (2022), against an average of $415823.5.
  • Year-over-year, Other Non-Current Assets tumbled 78.11% in 2022 and then surged 610.11% in 2024.
  • Corvus Pharmaceuticals' Other Non-Current Assets stood at $129000.0 in 2022, then crashed by 31.01% to $89000.0 in 2023, then soared by 610.11% to $632000.0 in 2024, then skyrocketed by 35.28% to $855000.0 in 2025, then skyrocketed by 101.17% to $1.7 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Other Non-Current Assets are $1.7 million (Q1 2026), $855000.0 (Q4 2025), and $852000.0 (Q3 2025).